DBV Technologies | DBVT - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amarin USD 18.97M 1.03M 2025-12
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
DBV Technologies USD 15.8M 2.4M 2026-09
Galectin Therapeutics USD 1.48M 110K 2024-06
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Incyte USD 364.27M 12.54M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
United Therapeutics USD 184.1M 22.6M 2026-09